Russia to reduce public procurements of certain anticancer drugs on federal level

Russia will significantly reduce public procurements of anti-cancer which are not included in the list of vital drugs due to the lack of funds, reports The Pharma Letter’s local correspondent.

These include drugs such as Abraxane (nanoparticle albumin-bound paclitaxel) from the USA’s Bristol Myers Squibb (NYSE: BMY) and Piqray (alpelisib) from the Swiss pharma giant Novartis (NOVN: VX),

This means that state purchases of these drugs will no longer be conducted on the federal level. Instead, the regions will now have to purchase these drugs from their own reserves.